Maravai LifeSciences (MRVI) Competitors $2.20 +0.17 (+8.37%) Closing price 04:00 PM EasternExtended Trading$2.32 +0.12 (+5.50%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRVI vs. NAMS, GMTX, RARE, OGN, RXRX, AMRX, MIRM, BHC, CPRX, and XENEShould you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include NewAmsterdam Pharma (NAMS), Gemini Therapeutics (GMTX), Ultragenyx Pharmaceutical (RARE), Organon & Co. (OGN), Recursion Pharmaceuticals (RXRX), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), Bausch Health Cos (BHC), Catalyst Pharmaceuticals (CPRX), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry. Maravai LifeSciences vs. Its Competitors NewAmsterdam Pharma Gemini Therapeutics Ultragenyx Pharmaceutical Organon & Co. Recursion Pharmaceuticals Amneal Pharmaceuticals Mirum Pharmaceuticals Bausch Health Cos Catalyst Pharmaceuticals Xenon Pharmaceuticals NewAmsterdam Pharma (NASDAQ:NAMS) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation. Is NAMS or MRVI more profitable? Maravai LifeSciences has a net margin of -67.14% compared to NewAmsterdam Pharma's net margin of -259.07%. Maravai LifeSciences' return on equity of -12.91% beat NewAmsterdam Pharma's return on equity.Company Net Margins Return on Equity Return on Assets NewAmsterdam Pharma-259.07% -27.27% -25.00% Maravai LifeSciences -67.14%-12.91%-6.87% Which has more risk and volatility, NAMS or MRVI? NewAmsterdam Pharma has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Do institutionals and insiders have more ownership in NAMS or MRVI? 89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 20.8% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 2.1% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend NAMS or MRVI? NewAmsterdam Pharma presently has a consensus price target of $41.20, suggesting a potential upside of 62.78%. Maravai LifeSciences has a consensus price target of $6.64, suggesting a potential upside of 201.77%. Given Maravai LifeSciences' higher probable upside, analysts clearly believe Maravai LifeSciences is more favorable than NewAmsterdam Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89Maravai LifeSciences 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has higher earnings and valuation, NAMS or MRVI? Maravai LifeSciences has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$45.56M62.37-$241.60M-$1.62-15.62Maravai LifeSciences$259.18M2.16-$144.85M-$1.14-1.93 Does the media prefer NAMS or MRVI? In the previous week, NewAmsterdam Pharma had 3 more articles in the media than Maravai LifeSciences. MarketBeat recorded 9 mentions for NewAmsterdam Pharma and 6 mentions for Maravai LifeSciences. NewAmsterdam Pharma's average media sentiment score of 0.71 beat Maravai LifeSciences' score of 0.28 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryMaravai LifeSciences beats NewAmsterdam Pharma on 9 of the 16 factors compared between the two stocks. Get Maravai LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRVI vs. The Competition Export to ExcelMetricMaravai LifeSciencesMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$515.69M$10.57B$5.44B$9.61BDividend YieldN/A2.01%4.61%4.14%P/E Ratio-1.9319.8629.7524.84Price / Sales2.1621.90449.4898.68Price / Cash3.2821.7436.4258.36Price / Book0.962.858.185.64Net Income-$144.85M$211.77M$3.26B$265.68M7 Day Performance-0.90%3.65%1.15%2.51%1 Month Performance-20.29%4.41%2.82%1.88%1 Year Performance-74.04%-9.77%28.41%24.00% Maravai LifeSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRVIMaravai LifeSciences3.6113 of 5 stars$2.20+8.4%$6.64+201.8%-77.7%$515.69M$259.18M-1.93610News CoverageUpcoming EarningsOptions VolumeNAMSNewAmsterdam Pharma3.5729 of 5 stars$23.42-0.8%$41.30+76.3%+46.6%$2.63B$45.56M-12.464News CoveragePositive NewsEarnings ReportAnalyst ForecastGMTXGemini TherapeuticsN/A$60.61+0.0%N/A+40.1%$2.63BN/A-60.6130Gap DownRAREUltragenyx Pharmaceutical4.3943 of 5 stars$27.61+1.0%$82.57+199.1%-43.1%$2.61B$590.69M-4.701,294Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionOGNOrganon & Co.4.7949 of 5 stars$9.96-2.4%$18.00+80.7%-52.2%$2.59B$6.40B3.464,000Earnings ReportDividend AnnouncementRXRXRecursion Pharmaceuticals2.1969 of 5 stars$6.31-2.8%$7.00+10.9%-15.1%$2.56B$58.84M-3.56400Earnings ReportAnalyst RevisionAMRXAmneal Pharmaceuticals3.6292 of 5 stars$8.17+1.4%$11.60+42.0%+20.6%$2.56B$2.83B-204.208,100Earnings ReportMIRMMirum Pharmaceuticals3.343 of 5 stars$51.49-0.7%$65.50+27.2%+53.5%$2.55B$336.89M-31.98140Trending NewsEarnings ReportAnalyst ForecastInsider TradeBHCBausch Health Cos4.6833 of 5 stars$6.88+1.6%$7.38+7.2%+10.1%$2.55B$9.73B-62.5520,700CPRXCatalyst Pharmaceuticals4.8838 of 5 stars$20.80-0.8%$32.83+57.9%+21.0%$2.54B$534.65M13.2580XENEXenon Pharmaceuticals3.0814 of 5 stars$30.97+2.2%$54.82+77.0%-16.7%$2.38B$7.50M-9.59210Upcoming EarningsOptions Volume Related Companies and Tools Related Companies NAMS Alternatives GMTX Alternatives RARE Alternatives OGN Alternatives RXRX Alternatives AMRX Alternatives MIRM Alternatives BHC Alternatives CPRX Alternatives XENE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRVI) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maravai LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
